drugset
drugset / Trial / NCT06214156

A Clinical Study of T3011 in Subjects With Advanced Melanoma

NCT06214156 ↗

Phase 1/2 Recruiting 42 enrolled Shanghai Pharmaceuticals Holding Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.

Timeline

Start
2024-01-26
Primary completion
2026-09-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject T3011 Other / unclassified — Other

Indications

melanoma